Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

35.78CHF
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
CHF35.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,559
52-wk High
CHF70.80
52-wk Low
CHF35.68

Select another date:

Mon, Jun 3 2019

BRIEF-Basilea Pharmaceutica Publishes Clinical Data For Anticancer Drug Candidates BAL101553

* REPORTS PUBLICATION OF CLINICAL DATA FOR ANTICANCER DRUG CANDIDATES BAL101553 IN GLIOBLASTOMA AND DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

BRIEF-Basilea Pharmaceutica: Strong European Cresemba Sales Trigger $5 Mln Milestone Payment

* STRONG EUROPEAN CRESEMBA® (ISAVUCONAZOLE) SALES TRIGGER USD 5 MILLION MILESTONE PAYMENT TO BASILEA FROM PFIZER

BRIEF-Basilea Says Adesh Kaul Appointed CFO

* BASILEA ANNOUNCES CHANGE IN THE MANAGEMENT COMMITTEE - ADESH KAUL APPOINTED CFO

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Basilea: Positive Interim Results From Registrational Phase 2 Study With Derazantinib

* BASILEA REPORTS POSITIVE INTERIM RESULTS FROM REGISTRATIONAL PHASE 2 STUDY WITH ONCOLOGY DRUG CANDIDATE DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA)

BRIEF-Basilea Preliminary FY Revenue At CHF 133 Mln

* BASILEA REPORTS STRONG, HIGHER THAN EXPECTED PRELIMINARY REVENUE OF CHF 133 MILLION FOR FINANCIAL YEAR 2018

Select another date: